Disease relevance of NAT6

• Characterization of a new SNP c767A/T (Arg222Trp) in the candidate TSG FUS2 on human chromosome 3p21.3: prevalence in Asian populations and analysis of association with nasopharyngeal cancer [1].

High impact information on NAT6

• The strongest FUSION 2 linkage results were on chromosomes 6 (maximum logarithm of odds score [MLS] = 2.30 at 95 cM) and 14 (MLS = 1.80 at 57 cM) [2].
• Here, we show that the putative tumour suppressor protein Fus-2 has homology to the catalytic domain of acetyltransferases [3].
• Since the Fus-2 gene maps to the chromosomal region 3p21.3, which contains at least one tumour suppressor gene, the N-acetyltransferase functions of Fus-2 may be relevant to its potential role in cancer [3].
• The FUS2 gene, encoding a novel cytoplasmic acetyltransferase, resides in the tumor suppressor gene region on human chromosome 3p21.3 and is considered a promising candidate tumor suppressor gene [1].
• Since nasopharyngeal carcinoma (NPC) is frequent in Southern China, Taiwan, Borneo and polar Canada, we further tested for the possible association of the FUS2 SNP with this form of endemic cancer [1].

Other interactions of NAT6

• The words were processed to produce three bandwidth conditions (100, 300, 600 Hz) and were administered via three presentation modes (binaural fusion 1, diotic, binaural fusion 2) [4].

Analytical, diagnostic and therapeutic context of NAT6

• It proved possible to demonstrate clinically that patients with an isolated ventral spondylodesis feel significantly better and experience significantly less pain in the area of spinal fusion than patients with ventro-dorsal fusion 2 and 5.4 years after the operation [5].

References